Cytek Biosciences Inc (CTKB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -6,020 | -15,663 | -16,603 | -6,169 | -12,148 |
| Depreciation Amortization | 10,490 | 7,749 | 4,940 | 2,460 | 9,230 |
| Income taxes - deferred | -2,886 | 0 | 0 | 0 | N/A |
| Accounts receivable | -5,428 | 3,901 | 10,153 | 4,235 | -7,332 |
| Accounts payable and accrued liabilities | 2,582 | 2,324 | 96 | 615 | -1,784 |
| Other Working Capital | 7,713 | 13,213 | 9,954 | 1,847 | -10,509 |
| Other Operating Activity | 18,928 | 11,858 | 1,621 | 969 | 27,824 |
| Operating Cash Flow | $25,379 | $23,382 | $10,161 | $3,957 | $5,281 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -79,062 | -16,812 | -1,985 | -5,132 | -43,935 |
| PPE Investments | -3,237 | -2,534 | -1,544 | -567 | -4,648 |
| Net Acquisitions | -471 | N/A | N/A | N/A | -44,896 |
| Purchase Of Investment | N/A | N/A | N/A | N/A | -236 |
| Purchase Sale Intangibles | -204 | -195 | -203 | -55 | -179 |
| Other Investing Activity | -204 | -195 | -203 | -55 | -179 |
| Investing Cash Flow | $-82,974 | $-19,541 | $-3,732 | $-5,754 | $-93,894 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 4,181 | 1,396 | 1,391 | 1,394 | N/A |
| Debt Repayment | -557 | -418 | -278 | -139 | -565 |
| Common Stock Issued | 1,015 | 877 | 730 | 506 | 1,468 |
| Common Stock Repurchased | -19,907 | -13,613 | -1,663 | 0 | -42,296 |
| Other Financing Activity | -554 | -424 | -278 | -148 | -419 |
| Financing Cash Flow | $-15,822 | $-12,182 | $-98 | $1,613 | $-41,812 |
| Exchange Rate Effect | 4,532 | 3,014 | 3,957 | 1,695 | -1,445 |
| Beginning Cash Position | 167,630 | 167,630 | 167,630 | 167,630 | 299,500 |
| End Cash Position | 98,745 | 162,303 | 177,918 | 169,141 | 167,630 |
| Net Cash Flow | $-68,885 | $-5,327 | $10,288 | $1,511 | $-131,870 |
| Free Cash Flow | |||||
| Operating Cash Flow | 25,379 | 23,382 | 10,161 | 3,957 | 5,281 |
| Capital Expenditure | -3,525 | -2,631 | -1,620 | -567 | -4,648 |
| Free Cash Flow | 21,854 | 20,751 | 8,541 | 3,390 | 633 |